Company Overview - Deere & Company (NYSE: DE) is a prominent manufacturer in the agricultural, construction, and forestry machinery sectors, recognized for its green and yellow equipment [1] - The company competes with major players such as Caterpillar and CNH Industrial [1] Stock Performance - The current stock price of DE is $469.87, reflecting a decrease of 5.67% or $28.26 [4] - The stock has fluctuated between $469.46 and $487.82 today, with a yearly high of $533.78 and a low of $403.01 [4] - DE's market capitalization is approximately $127 billion, with a trading volume of 5,471,364 shares on the NYSE [4] Analyst Insights - Jamie Cook from Truist Financial has set a price target of $612 for DE, indicating a potential increase of 30.25% from the current price [5][1] Investor Sentiment - Advisors Asset Management Inc. has reduced its stake in DE by 30.8%, now holding 8,434 shares valued at approximately $4.3 million after selling 3,753 shares [2] - Conversely, Brighton Jones LLC increased its stake by 39.1% during the fourth quarter, acquiring an additional 1,278 shares for a total of 4,548 shares valued at $1.9 million [3] - Mackenzie Financial Corp also raised its holdings by 9.6% in the same period, indicating confidence in DE's growth potential [3]

Group 1 - Actuate Therapeutics, Inc. (ACTU) closed at $6.9, with a 4.9% gain over the past four weeks, and a mean price target of $21.67 suggests a 214.1% upside potential [1] - The average price target ranges from a low of $20.00 to a high of $25.00, with a standard deviation of $2.89, indicating a strong agreement among analysts [2] - Analysts show optimism regarding ACTU's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] Group 2 - The Zacks Consensus Estimate for ACTU has increased by 0.9% due to one upward revision in earnings estimates over the last 30 days [12] - ACTU holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Group 1 - Shares of OppFi Inc. (OPFI) have increased by 1.5% over the past four weeks, closing at $9.76, with a mean price target of $14.5 indicating a potential upside of 48.6% [1] - The mean estimate includes three short-term price targets with a standard deviation of $1.32, where the lowest estimate of $13.50 suggests a 38.3% increase, and the highest estimate of $16.00 indicates a 63.9% increase [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 10.6% over the last 30 days, with two estimates moving higher and no negative revisions [12] - OPFI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Rush Street Interactive, Inc. (RSI) shows potential for significant upside, with a mean price target of $23 indicating a 28.5% increase from its current price of $17.9 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $2.56, indicating variability among analysts [2] - The lowest estimate is $18.00, suggesting a 0.6% increase, while the highest estimate is $27.00, indicating a potential surge of 50.8% [2] - Analysts' price targets can be misleading, as they often set overly optimistic targets influenced by business relationships [7][8] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding RSI's earnings prospects supports the expectation of an upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 23.9%, with two estimates moving higher and no negative revisions [12] - RSI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not reliably indicate the extent of potential gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Rapport Therapeutics, Inc. (RAPP) shares have increased by 9.5% in the last four weeks, closing at $29.43, with a potential upside of 75% based on Wall Street analysts' mean price target of $51.5 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $34.00 to a high of $80.00, with a standard deviation of $13.2, indicating variability among analysts [2] - The lowest estimate suggests a 15.5% increase from the current price, while the highest estimate indicates a potential upside of 171.8% [2] Analyst Sentiment - Analysts show a consensus that RAPP will report better earnings than previously estimated, which supports the expectation of a stock price increase [4][11] - The Zacks Consensus Estimate for the current year has risen by 7.4% over the past month, with four estimates increasing and no negative revisions [12] Zacks Rank - RAPP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Implications - While the consensus price target may not be a reliable indicator of the extent of RAPP's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Hinge Health Inc. (HNGE) has shown a 0.9% increase in stock price over the past four weeks, closing at $50.05, with analysts suggesting a potential upside of 29.6% based on a mean price target of $64.86 [1][11]. Price Targets - The average of 14 short-term price targets ranges from a low of $56.00 to a high of $72.00, with a standard deviation of $4.66, indicating a relatively high agreement among analysts [2][9]. - The lowest estimate suggests an 11.9% increase from the current price, while the highest estimate indicates a 43.9% upside [2]. Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with positive stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has increased by 4.6% over the past month, with seven estimates revised upward and no negative revisions [12]. Zacks Rank - HNGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the exact price movement, it does provide a useful guide for potential price direction [14].

Core Viewpoint - One Stop Systems, Inc. (OSS) shares have increased by 16.4% recently, with analysts suggesting a potential upside of 42.9% based on a mean price target of $8.5 [1][4]. Price Targets - The average price target for OSS is $8.5, with estimates ranging from a low of $8.00 to a high of $9.00, indicating potential increases of 34.5% to 51.3% from the current price [2][4]. - The standard deviation of $0.5 suggests a relatively high agreement among analysts regarding the price targets [2][9]. Analyst Sentiment - Analysts have shown increasing optimism about OSS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 16.7%, with no negative revisions reported [12]. Zacks Rank - OSS holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the direction indicated by these targets appears to be a useful guide for potential price movement [14].

Core Viewpoint - CareDx (CDNA) has shown a significant price increase of 24.7% over the past four weeks, with a mean price target of $22.8 indicating a potential upside of 28% from the current price of $17.81 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $5.54, where the lowest estimate is $14.00 (21.4% decline) and the highest is $28.00 (57.2% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about CareDx's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, two estimates have been revised upward, leading to a 38.8% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - CareDx holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Orion Energy Systems, Inc. (OESX) has shown a significant price increase of 41.2% over the past four weeks, with a mean price target of $17.83 indicating a potential upside of 26.4% from the current price of $14.11 [1] Price Targets and Analyst Consensus - The average price target for OESX ranges from a low of $15.00 to a high of $20.00, with a standard deviation of $2.57, suggesting a variability in analyst estimates [2] - The lowest estimate indicates a 6.3% increase, while the highest suggests a 41.7% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about OESX's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 57.1%, with two estimates moving higher and no negative revisions [12] - OESX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common metric for investors, relying solely on them for investment decisions may not be prudent due to potential biases in analyst estimates [3][10] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

Group 1 - Keros Therapeutics, Inc. (KROS) shares have increased by 14.1% over the past four weeks, closing at $17.32, with a mean price target of $23.25 indicating a potential upside of 34.2% [1] - The average price targets from analysts range from a low of $16.00 to a high of $35.00, with a standard deviation of $5.95, suggesting variability in estimates [2] - Analysts show strong agreement on KROS's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for KROS's current year earnings has increased by 484% over the past month, with six estimates revised upward and no negative revisions [12] - KROS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]